Oak Family Advisors LLC lessened its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 12.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,741 shares of the biopharmaceutical company’s stock after selling 795 shares during the quarter. Oak Family Advisors LLC’s holdings in Pfizer were worth $339,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. TimeScale Financial Inc. boosted its holdings in shares of Pfizer by 2.9% during the 4th quarter. TimeScale Financial Inc. now owns 6,978 shares of the biopharmaceutical company’s stock valued at $412,000 after acquiring an additional 196 shares in the last quarter. Bath Savings Trust Co boosted its holdings in shares of Pfizer by 0.5% during the 4th quarter. Bath Savings Trust Co now owns 39,684 shares of the biopharmaceutical company’s stock valued at $2,344,000 after acquiring an additional 200 shares in the last quarter. Fruth Investment Management raised its position in Pfizer by 0.7% during the 4th quarter. Fruth Investment Management now owns 29,313 shares of the biopharmaceutical company’s stock worth $1,730,000 after purchasing an additional 200 shares during the last quarter. Cortland Associates Inc. MO raised its position in Pfizer by 2.6% during the 4th quarter. Cortland Associates Inc. MO now owns 7,897 shares of the biopharmaceutical company’s stock worth $466,000 after purchasing an additional 201 shares during the last quarter. Finally, Clean Yield Group raised its position in Pfizer by 1.3% during the 4th quarter. Clean Yield Group now owns 15,535 shares of the biopharmaceutical company’s stock worth $917,000 after purchasing an additional 205 shares during the last quarter. Institutional investors and hedge funds own 64.96% of the company’s stock.
Several research analysts recently issued reports on the company. Mizuho lowered their target price on Pfizer from $56.00 to $55.00 in a research report on Thursday, February 10th. Morgan Stanley initiated coverage on Pfizer in a research report on Wednesday. They set an “equal weight” rating and a $55.00 target price for the company. SVB Leerink lifted their price objective on Pfizer from $52.00 to $56.00 and gave the stock a “market perform” rating in a research report on Wednesday, December 15th. UBS Group raised Pfizer from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $52.00 to $60.00 in a research report on Monday, December 13th. Finally, Barclays set a $54.00 price objective on Pfizer in a research report on Wednesday, February 9th. Eleven research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Buy” and an average target price of $58.00.
Pfizer (NYSE:PFE – Get Rating) last released its earnings results on Tuesday, February 8th. The biopharmaceutical company reported $1.08 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.23. The firm had revenue of $23.84 billion for the quarter, compared to analysts’ expectations of $24.20 billion. Pfizer had a net margin of 26.97% and a return on equity of 34.53%. The company’s quarterly revenue was up 104.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.42 earnings per share. On average, equities research analysts forecast that Pfizer Inc. will post 7.28 EPS for the current fiscal year.
Pfizer Profile (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- 3 Recession-Proof Stocks to Buy Now
- MarketBeat: Week in Review 4/4 – 4/8
- 3 Best Life Sciences Stocks to Buy Now
- The Institutional Insiders Are Buying WD-40 Company
- What’s Behind The Latest Surge In GameStop (NYSE: GME)?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.